Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 61

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1
Chunk 61
---
 from JHU-APL for the additional technology developed to enhance the bfLEAP™ platform. The July 8, 2022 JHU-APL license
provides the Company with new intellectual property and also encompasses most of the intellectual property from our original February
2018 license agreement with JHU-APL.

We
believe bfLEAP™ will inform and enable decision making throughout the development cycle:

●Discovery
                                            Phase - Analyze and categorize discovery phase data to better define highest-value leads
                                            from groups of candidates, for advancement to preclinical phase of development. Integrate
                                            data from high-throughput screening, pharmacodynamics assays, pharmacokinetics assays, and
                                            other key data sets to create the most accurate profile of a pool of therapeutic candidates.
                                            There is often a high degree of similarity among closely related therapeutics in a candidate
                                            pool - bfLEAP™ is able to harmonize disparate data streams for a more nuanced understanding
                                            of each candidate’s characteristics/potency.

●Pre-Clinical
                                            Data - Large-scale, multivariate analysis of pre-clinical and early-stage clinical data
                                            sets. In these settings, bfLEAP could be used to find novel drug targets, elucidate mechanism
                                            of action, predict potential off-target effects/side effects, uncover specific genetic/phenotypic
                                            background(s) with highest correlation to therapeutic response, etc. These insights from
                                            bfLEAP™ analysis can be used to inform decision making and study design at the subsequent
                                            step(s) of therapeutic and diagnostic development, including first-inhuman/Phase I randomized
                                            controlled trials.

 5 

●Clinical
                                            Development – Advanced, multivariate analysis of Phase I and Phase II clinical
                                            trials data, to find niche populations of highly responsive patients and/or inform patient
                                            selection for later-stage clinical trials. This can be used to decrease overall study risk
                                            for larger clinical trials - including Phase II trials, and any Phase III Registration Clinical
                                            Trials. The bfLEAP™ platform analysis can also be used to more precisely understand
                                            complex correlations between therapeutic treatment and adverse events, side effects, and
                                            other undesirable responses which could jeopardize clinical trial success.

Our
platform is agnostic to the disease indication or treatment modality and therefore we believe that it is of value in the development
of biologics or small molecules.

The
process for our drug asset enhancement program is to:

●ac